Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) passed below its 50 day moving average during trading on Thursday after an insider sold shares in the company. The stock has a 50 day moving average of $522.74 and traded as low as $517.82. Vertex Pharmaceuticals shares last traded at $520.66, with a volume of 1,176,919 shares trading hands.
Specifically, Director Sangeeta N. Bhatia sold 271 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $547.86, for a total value of $148,470.06. Following the completion of the sale, the director directly owned 4,653 shares of the company’s stock, valued at $2,549,192.58. This trade represents a 5.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $547,860.00. Following the sale, the director directly owned 1,109 shares in the company, valued at approximately $607,576.74. This represents a 47.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In other Vertex Pharmaceuticals news, EVP Charles Wagner, Jr. sold 15,286 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total value of $8,374,740.82. Following the sale, the executive vice president owned 31,764 shares of the company’s stock, valued at approximately $17,402,542.68. This represents a 32.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Wall Street Analyst Weigh In
Several research firms have weighed in on VRTX. Stifel Nicolaus raised their target price on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a report on Tuesday, November 3rd. JPMorgan Chase & Co. upped their price target on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Canaccord Genuity Group increased their price target on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research report on Tuesday, August 4th. Morgan Stanley dropped their price objective on shares of Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating for the company in a research note on Tuesday, November 3rd. Finally, Leerink Partners assumed coverage on shares of Vertex Pharmaceuticals in a research note on Monday, September 21st. They set an “outperform” rating and a $594.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $596.44.
Check Out Our Latest Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Trading Down 2.9%
The business has a fifty day moving average price of $522.74 and a 200 day moving average price of $485.01. The firm has a market capitalization of $132.01 billion, a price-to-earnings ratio of 33.50, a P/E/G ratio of 2.84 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.80 EPS. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.
Institutional Trading of Vertex Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the company. PCM Encore LLC lifted its holdings in Vertex Pharmaceuticals by 2.3% in the 3rd quarter. PCM Encore LLC now owns 2,177 shares of the pharmaceutical company’s stock worth $1,138,000 after buying an additional 49 shares in the last quarter. Defiance ETFs LLC boosted its position in Vertex Pharmaceuticals by 16.5% in the 3rd quarter. Defiance ETFs LLC now owns 1,165 shares of the pharmaceutical company’s stock valued at $609,000 after buying an additional 165 shares during the last quarter. Kestra Advisory Services LLC boosted its position in Vertex Pharmaceuticals by 46.1% in the 3rd quarter. Kestra Advisory Services LLC now owns 22,981 shares of the pharmaceutical company’s stock valued at $12,015,000 after buying an additional 7,249 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at about $13,862,000. Finally, DGS Capital Management LLC grew its stake in shares of Vertex Pharmaceuticals by 23.5% during the third quarter. DGS Capital Management LLC now owns 1,501 shares of the pharmaceutical company’s stock valued at $785,000 after acquiring an additional 286 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Recommended Stories
- Five stocks we like better than Vertex Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
